Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

68 results
Display

The Effects of Systemic Psoriasis Therapies on the C-Reactive Protein and the Neutrophil-Lymphocyte Ratio

Aktaş Karabay E, Aksu Çerman A, Demir D, Kıvanç Altunay I

BACKGROUND: Currently, no generally accepted laboratory marker for monitorizing the disease activity and therapy response of psoriasis is known. OBJECTIVE: The aim of the study is to evaluate the effects of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis

Lee S, Park YJ, Lee JY

BACKGROUND: Tumor necrosis factor-alpha (TNF-α) inhibitors (TNFis), which are the main treatment for ankylosing spondylitis (AS), have been reported not only to reduce the incidence of anterior uveitis (AU) but...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pustulotic Arthro-osteitis Improved with Anti TNF-α Inhibitor

Park HS, Kim JH, Kim HW, Kim SC

  • KMID: 2457688
  • Korean J Dermatol.
  • 2019 Aug;57(7):378-382.
Pustulotic arthro-osteitis (PAO) is a rare chronic inflammatory disorder characterized by inflammatory osteitis of the sternoclavicular joint and palmoplantar pustulosis. Here, we report a case of PAO that was successfully...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long Term Safety and Efficacy of Etanercept in Juvenile Idiopathic Arthritis in a Single Center

Bang MH, Kim KN

OBJECTIVE: Our aim was to investigate the long term safety and efficacy of etanercept in children with juvenile idiopathic arthritis (JIA). METHODS: The study subjects were the 90 JIA patients treated...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Experience with Etanercept Therapy and the Switching Pattern among Korean Patients with Psoriasis after Withdrawal of Etanercept

Choi CW, Lee JS, Yu DA, Kim BR, Youn SW

BACKGROUND: The efficacy and safety of etanercept in the treatment of psoriasis has been proven, and the drug was approved for the treatment of moderate to severe psoriasis. However, there...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Anti-Tumor Necrosis Factor Therapy in Intestinal Behçet's Disease

Park J, Cheon JH

Intestinal Behçet's disease is a rare, immune-mediated chronic intestinal inflammatory disease; therefore, clinical trials to optimize the management and treatment of patients are scarce. Moreover, intestinal Behçet's disease is difficult...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
IgA nephropathy in a patient with ankylosing spondylitis well controlled with etanercept

Lee DH, Kim GT, Hwang NK, Kim EH

Ankylosing spondylitis (AS) can involve the eye, gastrointestinal system, cardiopulmonary system, skin, kidneys, and spinal and peripheral joints. It is rarely accompanied by immunoglobulin A (IgA) nephropathy. Although IgA is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Transaminase Changes in Korean Rheumatoid Arthritis Patients with Chronic Hepatitis C after Biologic Therapy

Kwon HM, Shin K, Moon JY, Lee SS, Chung WT, Lee J, Lee SH, Kang SW, Suh CH, Hong SJ, Song R, Choe JY, Song YW

OBJECTIVE: Coexisting chronic hepatitis C can be problematic when treating rheumatoid arthritis (RA). This study examined the changes in the transaminase and viral load in hepatitis C virus (HCV)-infected RA...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Drug survival of tumor necrosis factor α inhibitors in patients with ankylosing spondylitis in Korea

Jeong H, Eun YH, Kim IY, Kim H, Ahn JK, Lee J, Koh EM, Cha HS

BACKGROUND/AIMS: To evaluate drug survival of the tumor necrosis factor α inhibitors (TNFi) and risk factors for the drug discontinuation in patients with ankylosing spondylitis (AS). METHODS: We retrospectively evaluated 487...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Risk of Herpes Zoster in Patients with Rheumatoid Arthritis Undergoing Biologic Disease-Modifying Therapy

Kwon HM, Lee SJ, Yang JA, Choi Y, Park JK, Lee EY, Song YW, Lee EB

OBJECTIVE: Rheumatoid arthritis (RA) patients suffer from an increased risk of herpes zoster (HZ) partially due to immunosuppressant medications. This study investigated HZ in RA patients treated with biologic disease-modifying...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparative efficacy of biological agents in methotrexate-refractory rheumatoid arthritis patients: a Bayesian mixed treatment comparison

Choi M, Hyun MK, Choi S, Tchoe HJ, Lee SY, Son KM, Kim MJ, Jung YO, Kim HA

BACKGROUND/AIMS: Biological agents (biologics) targeting proinflammatory signaling have emerged as an important treatment option in rheumatoid arthritis (RA). Despite the clinical effectiveness of biologics for patients with RA who do...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tumor Necrosis Factor Alpha Blocker-Induced Erythrodermic Sarcoidosis in with Juvenile Rheumatoid Arthritis: A Case Report and Review of the Literature

Park SK, Hwang PH, Yun SK, Kim HU, Park J

The development of cutaneous sarcoidosis as a paradoxical adverse event of tumor necrosis factor alpha (TNF-α) blockers has been reported in the literature; however, an erythrodermic form of cutaneous sarcoidosis...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tumor Necrosis Factor Blockade Stimulates Circulating Osteoblastic Lineage Cells Activity while Reducing Circulating Osteoclasts

Lim MJ, Kwon SR, Jung KH, Park W

OBJECTIVE: This study examines the effects of tumor necrosis factor (TNF) blockade on markers of bone metabolism in peripheral blood from active rheumatoid arthritis (RA) patients. METHODS: Eighteen patients (16 women,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Recurrent macrophage activation syndrome since toddler age in an adolescent boy with HLA B27 positive juvenile ankylosing spondylitis

Park JH, Seo YM, Han SB, Kim KH, Rhim JW, Chung NG, Kim MS, Kang JH, Jeong DC

Recurrent macrophage activation syndrome (MAS) is very rare. We present the case of an adolescent boy with human leukocyte antigen (HLA) B27-positive ankylosing spondylitis (AS), who experienced episodes of recurrent...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dose Optimization for Single Intradiscal Administration of the Tumor Necrosis Factor-α Inhibitor, Etanercept, in Rat Disc Injury Models

Inage K, Orita S, Yamauchi K, Suzuki T, Suzuki M, Sakuma Y, Kubota G, Oikawa Y, Sainoh T, Sato J, Fujimoto K, Shiga Y, Abe K, Kanamoto H, Inoue M, Kinoshita , Takahashi , Ohtori S

STUDY DESIGN: Experimental animal study. PURPOSE: We aimed to determine the optimal dose of a single direct injection of the tumor necrosis factor (TNF)-α inhibitor, etanercept, by using the rat model...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Case of Sarcoidosis That Improved upon Discontinuation of Etanercept

Kang JH, Ahn JH, Yu JE, Kim JE, Yim YR, Lee JW, Lee KE, Park DJ, Wen L, Park YW, Lee SS

A 31-year-old man who had been prescribed etanercept over a 3-year period for treatment of ankylosing spondylitis presented with newly developed dry cough, chills, myalgia, and weight loss. Chest computed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Cost-Minimization Analysis of Biologic Disease-Modifying Antirheumatic Drugs Administered by Subcutaneous Injections in Patients with Rheumatoid Arthritis

Park SH, Lee MY, Lee EK

BACKGROUND: The subcutaneous formulation of biologic disease-modifying antirheumatic drugs (DMARDs) was preferred due to favored self-administration and would be an economical treatment option for patients with rheumatoid arthritis. This study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of Drug Utilization for Patients with Ankylosing Spondylitis

Kang HB, Je NK

BACKGROUND & OBJECT: Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes ankylosis and deformation of axial joints. Since current medicine cannot cure the disease yet, alleviating pain and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Incidence of Uveitis in Ankylosing Spondylitis Patients Undergoing Tumor Necrosis Factor Inhibiting Therapy in Korea

Koo BS, Hong S, Kim YJ, Lee CK, Yoo B, Kim YG

OBJECTIVE: The purpose of this study is to evaluate the outcome of uveitis in ankylosing spondylitis (AS) during tumor necrosis factor (TNF)-inhibiting therapy and to compare the incidence rate of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The use of biologics for severe psoriasis

Youn SW

Psoriasis is a life-long chronic relapsing dermatosis that shows waxing and waning of disease despite of a lot of conventional treatment. Severe psoriasis, usually defined by a psoriasis area and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr